[68Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas

Maria Breun, Camelia M. Monoranu, Almuth F. Kessler, Cordula Matthies, Mario Löhr, Carsten Hagemann, Andreas Schirbel, Steven P. Rowe, Martin G. Pomper, Andreas K. Buck, Hans Jürgen Wester, Ralf Ingo Ernestus, Constantin Lapa

Research output: Contribution to journalArticlepeer-review


We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pretreated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

Original languageEnglish (US)
Article number503
JournalFrontiers in Oncology
Issue numberJUN
StatePublished - 2019


  • CXCR4
  • Molecular imaging
  • PET/CT
  • Pentixafor
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '[<sup>68</sup>Ga]-pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas'. Together they form a unique fingerprint.

Cite this